Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers

Helen Mactier; Poppy McLaughlin; Cheryl Gillis; Michael David Osselton

doi:10.1055/s-0037-1600917

American Journal of Perinatology, Table of Contents

Am J Perinatol 2017; 34(09): 918-921
DOI: 10.1055/s-0037-1600917

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers

Authors

Helen Mactier

¹Neonatal Unit, Princess Royal Maternity, Glasgow, United Kingdom
Poppy McLaughlin

²Department of Anthropology and Forensic Science, Bournemouth University, Fern Barrow, Poole, United Kingdom
Cheryl Gillis

¹Neonatal Unit, Princess Royal Maternity, Glasgow, United Kingdom
Michael David Osselton

²Department of Anthropology and Forensic Science, Bournemouth University, Fern Barrow, Poole, United Kingdom

Abstract

Background Neonatal abstinence syndrome (NAS) in infants of methadone-maintained opioid-dependent (MMOD) mothers cannot be predicted in individual cases. We investigated whether variation in infant genotype is associated with severity of NAS.

Methods This is a pilot observational cohort study of 21 MMOD mothers and their newborns. Infant buccal swabs were obtained soon after delivery, together with a maternal blood sample for the determination of maternal plasma methadone concentration. Genomic variation in five opioid-related genes (ABCB1, COMT, CYP2B6, CYP2D6, and OPRM1) was ascertained from infant buccal swabs and related to need for pharmacological treatment of NAS.

Results Out of 21 infants, 11 (52%) required treatment for NAS. Mothers of treated infants tended to have been prescribed higher doses of methadone, but plasma methadone concentrations did not differ between mothers of treated or untreated babies. Treated and untreated babies did not differ in terms of method of feeding. Treated infants were more likely to carry the normal (homozygous) allele at 516 and 785 regions of CYP2B6 gene (p = 0.015 and 0.023, respectively). There were no differences in any other genes between infants who did or did not require treatment for NAS.

Conclusion Genomic variation in CYP2B6 may explain, at least in part, severity of NAS.

Keywords

neonatal abstinence syndrome - newborn - methadone - genotype

Full Text

References

References
1 Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006; 117 (06) e1163-e1169
2 Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009; 116 (05) 665-671
3 Cleary BJ, Donnelly JM, Strawbridge JD. , et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011; 204 (02) 139.e1-139.e9
4 Lewis T, Dinh J, Leeder JS. Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: knowledge deficits and prospects for future research. Clin Pharmacol Ther 2015; 98 (03) 309-320
5 NCBI database of Short Genetic Variations (dbSNP). Available at: https://www.ncbi.nlm.nih.gov/snp ; Accessed December 15, 2016
6 Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010; 88 (03) 383-389
7 Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One 2014; 9 (01) e86114 . Doi: 10.1371/journal.pone.0086114
8 Gadel S, Crafford A, Regina K, Kharasch ED. Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Drug Metab Dispos 2013; 41 (04) 709-713
9 Wachman EM, Hayes MJ, Brown MS. , et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309 (17) 1821-1827
10 Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975; 14 (06) 592-594
11 Tolia VN, Patrick SW, Bennett MM. , et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015; 372 (22) 2118-2126
12 Doberczak TM, Kandall SR, Friedmann P. Relationships between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993; 83: 936-940
13 McGlone L, Hamilton R, McCulloch DL. , et al. Neonatal visual evoked potentials are altered in infants born to mothers prescribed methadone in pregnancy. Pediatrics 2013; 131: e857-e863
14 Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368 (9536): 704 . Doi: 10.1016/S0140-6736(06)69255-6